EA201200526A1 - Поливалентные антитела, стабилизированные дисульфидом - Google Patents

Поливалентные антитела, стабилизированные дисульфидом

Info

Publication number
EA201200526A1
EA201200526A1 EA201200526A EA201200526A EA201200526A1 EA 201200526 A1 EA201200526 A1 EA 201200526A1 EA 201200526 A EA201200526 A EA 201200526A EA 201200526 A EA201200526 A EA 201200526A EA 201200526 A1 EA201200526 A1 EA 201200526A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disulfide
specificity
antibodies
fab
polyvalent antibodies
Prior art date
Application number
EA201200526A
Other languages
English (en)
Russian (ru)
Inventor
Ральф Адамс
Лора Ханкок
Сэм Филип Хейвуд
Original Assignee
Юсб Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2009/002310 external-priority patent/WO2010035012A1/en
Application filed by Юсб Фарма С.А. filed Critical Юсб Фарма С.А.
Publication of EA201200526A1 publication Critical patent/EA201200526A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA201200526A 2009-09-25 2010-09-24 Поливалентные антитела, стабилизированные дисульфидом EA201200526A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2009/002310 WO2010035012A1 (en) 2008-09-26 2009-09-25 Biological products
GBGB1005063.1A GB201005063D0 (en) 2010-03-25 2010-03-25 Biological products
PCT/GB2010/001803 WO2011036460A1 (en) 2009-09-25 2010-09-24 Disulfide stabilised multivalent antibodies

Publications (1)

Publication Number Publication Date
EA201200526A1 true EA201200526A1 (ru) 2012-11-30

Family

ID=42228366

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200526A EA201200526A1 (ru) 2009-09-25 2010-09-24 Поливалентные антитела, стабилизированные дисульфидом

Country Status (12)

Country Link
US (1) US20120316324A1 (enExample)
EP (1) EP2480577B1 (enExample)
JP (2) JP5931730B2 (enExample)
CN (2) CN105315374A (enExample)
BR (1) BR112012006492A2 (enExample)
CA (1) CA2773286C (enExample)
EA (1) EA201200526A1 (enExample)
ES (1) ES2736649T3 (enExample)
GB (1) GB201005063D0 (enExample)
IN (1) IN2012DN02535A (enExample)
TR (1) TR201910213T4 (enExample)
WO (1) WO2011036460A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
ES2667258T3 (es) * 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
JP5986207B2 (ja) * 2011-09-06 2016-09-06 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 生体高分子複合体を分析するための方法およびその使用
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
US9803004B2 (en) 2011-11-11 2017-10-31 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
US9989524B2 (en) 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
CA2900154A1 (en) * 2013-02-05 2014-08-14 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US9844607B2 (en) 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
AU2014214997A1 (en) * 2013-02-05 2015-08-20 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
JP2016509014A (ja) 2013-02-08 2016-03-24 ステムセントリックス， インコーポレイテッド 新規の多特異的構成物
JP6499087B2 (ja) * 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
WO2014131711A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
MX371328B (es) * 2013-08-30 2020-01-27 Aprilbio Co Ltd Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion.
PL3065774T3 (pl) 2013-11-06 2021-12-13 Janssen Biotech, Inc Przeciwciała anty-ccl17
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
WO2017106684A2 (en) 2015-12-17 2017-06-22 Janssen Biotech, Inc. Antibodies specifically binding hla-dr and their uses
MX2018008308A (es) * 2016-01-11 2019-05-15 Inhibrx Inc Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
CN107674122A (zh) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
IL271127B2 (en) * 2017-06-05 2024-10-01 Numab Therapeutics AG Novel anti-hsa antibodies
RU2019142330A (ru) 2017-06-30 2021-07-30 Займворкс, Инк. Стабилизированные химерные fab
TW201930358A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
KR102839330B1 (ko) 2018-01-15 2025-07-30 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
CN110551216B (zh) * 2018-05-31 2022-11-18 信达生物制药(苏州)有限公司 多价抗ox40抗体及其用途
CN115667316A (zh) * 2020-06-30 2023-01-31 和铂医药(上海)有限责任公司 Fab-HCAb结构的结合蛋白
CN115698088A (zh) * 2020-06-30 2023-02-03 和铂医药(上海)有限责任公司 免疫细胞衔接器多特异性结合蛋白及其制备和应用
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
EP4192880A4 (en) 2020-08-05 2025-04-30 Synthekine, Inc. IL10 receptor-binding molecules and methods of use
US12234291B2 (en) 2020-08-05 2025-02-25 Synthekine, Inc. IL2RB binding molecules and methods of use
US12077594B2 (en) 2020-08-05 2024-09-03 Synthekine, Inc. IL2RG binding molecules and methods of use
US12012457B1 (en) 2020-08-05 2024-06-18 Synthekine, Inc. IL23R binding molecules and methods of use
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022031870A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. IL27Rα BINDING MOLECULES AND METHODS OF USE
JP7819178B2 (ja) 2020-08-05 2026-02-24 シンセカイン インコーポレイテッド ＩＬ１０Ｒｂ結合分子および使用方法
WO2022031885A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il10ra binding molecules and methods of use
US11859001B2 (en) 2020-08-05 2024-01-02 Synthekine, Inc. IL12RB1-Binding molecules and methods of use
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
WO2022032025A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr binding synthetic cytokines and methods of use
CN116829585A (zh) 2020-08-05 2023-09-29 辛德凯因股份有限公司 Il27受体结合相关的组合物和方法
BR112023001723A2 (pt) 2020-08-05 2023-05-02 Synthekine Inc Moléculas de ligação à gp130 e métodos de uso
US12291572B2 (en) 2020-08-05 2025-05-06 Synthekine, Inc. IL12 receptor synthetic cytokines and methods of use
US20230374148A1 (en) 2020-10-15 2023-11-23 UCB Biopharma SRL Binding molecules that multimerise cd45

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
GB9221657D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
DE19653722C2 (de) 1996-12-10 2000-06-29 Brose Fahrzeugteile Beidseitig wirkende Verstellvorrichtung
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
NZ336839A (en) 1997-02-21 2001-08-31 Genentech Inc Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
JP2002536968A (ja) * 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
MXPA02012867A (es) 2000-06-29 2003-09-05 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US20040071705A1 (en) 2002-06-21 2004-04-15 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
HUE026278T2 (en) 2003-07-01 2016-05-30 Ucb Biopharma Sprl Modified Fab antibody fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
CN101448853A (zh) * 2006-03-17 2009-06-03 比奥根艾迪克Ma公司 稳定的多肽组合物
CN103073639A (zh) * 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
US8629246B2 (en) * 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
WO2010035012A1 (en) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products

Also Published As

Publication number Publication date
ES2736649T3 (es) 2020-01-03
CN105315374A (zh) 2016-02-10
CN102549018A (zh) 2012-07-04
TR201910213T4 (tr) 2019-07-22
CA2773286A1 (en) 2011-03-31
EP2480577A1 (en) 2012-08-01
WO2011036460A1 (en) 2011-03-31
BR112012006492A2 (pt) 2016-11-22
JP5931730B2 (ja) 2016-06-08
CN102549018B (zh) 2015-11-25
GB201005063D0 (en) 2010-05-12
CA2773286C (en) 2020-10-20
JP2013505923A (ja) 2013-02-21
EP2480577B1 (en) 2019-04-10
JP2016106126A (ja) 2016-06-16
IN2012DN02535A (enExample) 2015-08-28
US20120316324A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
IN2012DN02535A (enExample)
EA201100527A1 (ru) Биологические продукты
EA201391159A1 (ru) Hla-рестриктированные пептидоспецифические антигенсвязывающие белки
RU2011148913A (ru) Иммуноглобулин с двумя вариабельными доменами и его применение
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
EP2535351A3 (en) Dual specificity antibody fusions
WO2016154047A3 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ623706A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
BRPI0715989A8 (pt) "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição"
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
WO2008097817A3 (en) Multivariable antigens complexed with targeting humanized monoclonal antibody
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
AU2010234031A8 (en) Trivalent, bispecific antibodies
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
JP2019523651A5 (enExample)
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
NZ701444A (en) Antibodies to matrix metalloproteinase 9
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
NZ720765A (en) Antibodies and methods of use
EA201691782A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
EA201691779A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения